Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Inclusion criteria

• Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD
• Aged 50 years or older
• Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye

Exclusion criteria

• No prior ocular or systemic treatment or surgery for neovascular AMD in the study eye
• History of or current clinical evidence in the study eye of:

• aphakia
• diabetic macular edema
• any ocular inflammation or infections
• pathological myopia
• retinal detachment
• advanced glaucoma
• significant media opacity, including cataract
• History or evidence of the following surgeries in the study eye:

• penetrating keratoplasty or vitrectomy;
• corneal transplant;
• corneal or intraocular surgery within 3 months of Screening
• Uncontrolled hypertension despite use of antihypertensive medications
• Participation in any investigational drug or device study, systemic or ocular, within past 3 months
• Women who are pregnant or nursing
• Known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation